Exosomes are getting a lot of attention right now in the orthobiologic space. They’re often marketed as “the next big thing,” especially for joint pain or osteoarthritis. But while the science behind exosomes is fascinating and rapidly evolving, it’s important to be clear about where this technology actually stands today.
A 2022 review published in Frontiers in Cell and Developmental Biology (“Exosomes in osteoarthritis”) summarizes what we currently know about exosomes and their potential role in cartilage repair and joint inflammation (1).
Here’s the key takeaway from the paper itself:
“…these studies are still in the primary research stage; thus, exosomes have not been applied in the clinical treatment of OA.”
This is critical. Most of the research the paper evaluates involves in-vitro studies (lab models) or animal models – not well-controlled human trials.
What Are Exosomes?
Exosomes are tiny vesicles released by cells. They act like “messenger packages,” carrying signals like:
- mRNAs
- long non-coding RNAs
- proteins
The review shows that exosomes may help regulate cartilage breakdown, inflammation, and repair. But again, this is primarily bench science. Not real-world clinical use.
Why Exosomes Are Not “Prime Time” Medicine Yet
According to the review and current state of the field, exosomes face major real-world limitations:
| Issue | Why It Matters |
| No standardization | Dose, source cells, processing methods vary wildly |
| Manufacturing complexity | These lipid bilayer vesicles are hard to produce, store, and deliver |
| Regulatory status | No FDA-approved clinical exosome products for OA |
| Evidence stage | Almost no high-level human clinical trials |
So while the research is exciting, exosomes are not yet ready for routine clinical use.
What Is Ready for Clinical Use Today?
PRP and Bone Marrow Concentrate (BMC) are the orthobiologic tools with:
- FDA-cleared preparation devices
- Years of real-world clinical use
- Human safety data
- Published randomized controlled trials
These treatments use a patient’s own biologic material to support healing activity and joint function, safely and within current regulatory frameworks.
| Treatment | Where We Are Today |
| PRP | Widely used, Level I and II human clinical trials support use in knee OA |
| Bone Marrow Concentrate (BMC) | Cellular therapy with established clinical experience and long history of orthopedic application |
| Exosomes | Still basic science – not appropriate for routine clinical care |
The Bottom Line
Exosomes may one day become an important tool in orthopedic regenerative medicine.
But today, the most responsible and clinically supported approach is still patient-derived PRP and BMC.
We follow the science, and we don’t jump ahead of it.
If You’re Interested in Non-Surgical Knee Care, We Can Help
At New Regeneration Orthopedics, our physicians specialize in image-guided orthobiologic procedures using your own platelets and cells—backed by published evidence and real clinical outcomes.
If you’re trying to avoid surgery, or you’re not ready for a joint replacement, you don’t have to guess what’s right for your knee.
Schedule a consultation today and get a personalized treatment plan grounded in evidence, not hype.
Citations:
- Fan Wen-Jin , Liu Di , Pan Lin-Yuan , Wang Wei-Yang , Ding Yi-Lan , Zhang Yue-Yao , Ye Rui-Xi , Zhou Yang , An Sen-Bo , Xiao Wen-Feng, Exosomes in osteoarthritis: Updated insights on pathogenesis, diagnosis, and treatment, Frontiers in Cell and Developmental Biology, Volume 10, 2022. PMID: 35978976
